ADHD - Alcobra Ltd. - Ordinary Shares

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Associated Press6 months ago

    Alcobra reports 3Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 9 cents. The company's shares closed at $1.35. A year ago, they were trading at $1.91. _____ This story was generated by Automated ...

  • Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?
    Simply Wall St.7 months ago

    Should You Be Concerned About Alcobra Ltd’s (ADHD) Risks?

    If you are looking to invest in Alcobra Ltd’s (NASDAQ:ADHD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Associated Press9 months ago

    Alcobra reports 2Q loss

    On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 13 cents. The company's shares closed at $1.03. A year ago, they were trading at $4.91. _____ This story was generated by ...

  • BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
    Zacks10 months ago

    BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session

    BioLine Rx Ltd (BLRX) shares rise over 5% in the last trading session.

  • New Strong Buy Stocks for July 20th
    Zacks10 months ago

    New Strong Buy Stocks for July 20th

    New Strong Buy Stocks for July 20th

  • Reuters11 months ago

    Shire wins U.S. approval for long-acting ADHD drug

    Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The U.S. Food and Drug Administration (FDA) green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin-based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the overnight FDA news.

  • Reuterslast year

    Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study

    Swiss biotech NLS Pharma AG said on Wednesday mid-stage trial data showed that its drug to treat attention deficit hyperactivity disorder (ADHD) greatly reduced symptoms in adults, paving the way for a late-stage trial. ADHD is a chronic condition characterized by hyperactivity, impulsive behavior and a difficulty in sustaining focus. NLS' drug, mazindol, is a non-stimulant, but trial data showed it could be as effective as a stimulant.

  • Associated Presslast year

    Alcobra reports 1Q loss

    The Tel Aviv, Israel-based company said it had a loss of 13 cents per share. The company's shares closed at $1.13. A year ago, they were trading at $5.12. _____ This story was generated by Automated Insights ...